Bronnen:
Smoot K, Chen C, Gervasi-Follmar T, et al. Evaluating the Efficacy and Safety of Transitioning Patients from Natalizumab to Ocrelizumab (OCTAVE). AAN 2019, P3.2-056.,Vollmer B, Nair K, Corboy J, et al. Characteristics of Patients Switching from Anti-CD20 Therapy to Natalizumab in the Treatment of Multiple Sclerosis. AAN 2019, P3.2-103.,Ziemssen T, Ettle B, Schulze-Topphoff U. Effectiveness and Safety of Fingolimod in Patients Switching from Dimethy Fumarate, Teriflunomide, and Daclizumab in Daily Clinical Routine: Interim Results from PANGAEA 2.0. AAN 2019, P3.2-075.,Gonzalez I, Peña J, Oterino Duran A, et al. Alemtuzumab Outcomes After Switching From Fingolimod In Real-Life Clinical Practice. AAN 2019, P3.2-050.
Smoot K, Chen C, Gervasi-Follmar T, et al. Evaluating the Efficacy and Safety of Transitioning Patients from Natalizumab to Ocrelizumab (OCTAVE). AAN 2019, P3.2-056.,Vollmer B, Nair K, Corboy J, et al. Characteristics of Patients Switching from Anti-CD20 Therapy to Natalizumab in the Treatment of Multiple Sclerosis. AAN 2019, P3.2-103.,Ziemssen T, Ettle B, Schulze-Topphoff U. Effectiveness and Safety of Fingolimod in Patients Switching from Dimethy Fumarate, Teriflunomide, and Daclizumab in Daily Clinical Routine: Interim Results from PANGAEA 2.0. AAN 2019, P3.2-075.,Gonzalez I, Peña J, Oterino Duran A, et al. Alemtuzumab Outcomes After Switching From Fingolimod In Real-Life Clinical Practice. AAN 2019, P3.2-050.